Novo Nordisk buys hemophilia A program from 2seventy Bio
Novo Nordisk acquired the hemophilia A program and gene-editing technology rights of 2seventy Bio, with 2seventy staffers…
Articles by Margarida Maia, PhD
AI-assisted ultrasounds may better detect joint bleeding, inflammation
Artificial intelligence (AI) can comb through ultrasound scans to detect joint bleeding and inflammation occurring as a result of…
HCB-101 shows promise for diseases due to nonsense mutations
HCB-101, hC Bioscience’s lead candidate to overwrite certain mutations that lead to hemophilia A, can reach the liver…
Cyclophosphamide therapy may be better option in some AHA cases
Added to steroids, rituximab seems to be as safe and effective as cyclophosphamide therapy at controlling bleeds and wiping…
Immune tolerance induction results don’t vary among races, ethnicities
Immune tolerance induction (ITI), a type of treatment that’s designed to eliminate neutralizing antibodies, or inhibitors, against clotting factors for…
New partners to develop universal gene therapy for hemophilia
ReciBioPharm and GeneVentiv Therapeutics are teaming up to advance the development of GENV-HEM, a gene…
Fewer bleeds after switch to Jivi from Kovaltry, study finds
Switching to Jivi (damoctocog alfa pegol), an extended half-life replacement therapy, from Kovaltry (octocog alfa), may help adults…
Study finds muscle loss common in hemophilia A with joint bleeds
Sarcopenia, or loss of muscle mass and strength, may occur in as many as half of adults with severe…
Preventive therapy may lead to less joint damage in hemophilia patients
A real-world study in Spain found that, among hemophilia patients, those with hemophilia A may have have worse joint…
Preventive Jivi found to safely reduce bleeds in hemophilia A
Individually tailored prophylaxis, or preventive treatment, with Jivi (damoctocog alfa pegol) nearly halved the number of annual bleeding episodes…